CDKN2B-AS1 and ovarian cancer: Several lines of previous studies have the similar results as ours, for instance, the up-regulated ANRIL was observed in ovarian cancer patients, which was associated with major clinicopathological features of ovarian tumor, and predicted the poor prognosis [12].